Table 5. The effects of rs9923231, rs7294, rs1057910, rs2108622, rs699664 on warfarin maintenance dose and plasma concentration.
| SNP | Genotype | N | Maintenance dose(mg/w) | Coefficient* | p* | Adjusted R2* | N | Plasma concentration (ng/ml) | Coefficient △ | p △ | Adjusted R2△ |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 158 | 0.320 | 92 | 0.267 | ||||||||
| VKORC1 rs9923231 | AA | 134 | 19.21±5.66 | 79 | 1117.29±323.23 | ||||||
| AG | 23 | 28.62±8.02 | 1.398 | <0.001 | 12 | 1675.73±431.09 | - | - | |||
| GG | 1 | 43.75 | 1 | 2298.50 | |||||||
| VKORC1 rs7294 | TT | 1 | 43.75 | 1 | 2298.50 | ||||||
| TC | 22 | 27.87±8.80 | - | 0.297 | 12 | 1675.73±431.09 | 0.527 | <0.001 | |||
| CC | 135 | 19.40±5.75 | 79 | 1117.29±323.23 | |||||||
| CYP2C9 rs1057910 | AA | 147 | 21.21±6.98 | 86 | 1200.78±399.18 | ||||||
| AC | 10 | 15.31±5.26 | -0.994 | <0.001 | 6 | 1234.23±470.14 | - | 0.326 | |||
| CC | 1 | 4.38 | - | - | |||||||
| CYP4F2 rs2108622 | AA | 4 | 22.42±7.66 | 3 | 1161.07±144.99 | ||||||
| AG | 54 | 22.21±6.40 | - | 0.056 | 27 | 1284.63±475.94 | - | 0.203 | |||
| GG | 100 | 19.87±7.39 | 62 | 1169.43±372.61 | |||||||
| GGCX rs699664 | TT | 24 | 22.53±7.34 | 10 | 1405.36±560.57 | ||||||
| TC | 72 | 21.06±7.09 | - | 0.134 | 50 | 1158.14±352.51 | - | 0.143 | |||
| CC | 62 | 19.66±7.01 | 32 | 1209.76±410.63 |
Analyzed by stepwise multiple linear regression.
*:the dependent variable was maintenance dose and the independent variables included age, body weight, gender, rs9923231, rs1057910, rs7294, rs2108622 and rs699664;
p *:showed the effects of 5 SNPs on the maintenance dose;
Adjusted R2*:showed the contribution of rs9923231and rs1057910 to the variability in warfarin maintenance dose.
△:the dependent variable was plasma concentration and the independent variables included age, body weight, gender, rs9923231, rs1057910, rs7294, rs2108622 and rs699664.
p △:showed the effects of 5 SNPs on the plasma concentration;
Adjusted R2△: showed the contribution of rs7294 to the plasma concentration.